Abstract：
BACKGROUND: Finerenone, a non-steroidal mineralocorticoid receptor antagonist, has previously demonstrated its efficacy and safety in chronic kidney disease (CKD) associated with diabetes mellitus. Given its therapeutic potential, finerenone has been preliminarily explored in clinical practice for non-diabetic CKD patients. The effectiveness and safety in this population require further investigation in a real-world setting.
METHODS: This retrospective, real-world analysis included non-diabetic CKD patients receiving finerenone. The main clinical outcomes assessed were changes in urinary albumin-to-creatinine ratio (UACR) and estimated glomerular filtration rate (eGFR). Serum potassium (sK+) levels were also monitored. Data were collected at baseline, and then at 1 month and 3 months following treatment initiation.
RESULTS: Totally, 16 patients were included. There was a notable decrease in UACR from 1-month post-treatment, with a further reduction at 3 months, resulting in a median reduction of 200.41 mg/g (IQR, 84.04-1057.10 mg/g; P = 0.028; percent change, 44.52% [IQR, 31.79-65.42%]). The average eGFR at baseline was 80.16 ml/min/1.73m2, with no significant change after 1 month (80.72 ml/min/1.73m2, P = 0.594) and a slight numerical increase to 83.45 ml/min/1.73m2 (P = 0.484) after 3 months. During the 3-month follow-up, sK+ levels showed only minor fluctuations, with no significant differences compared to baseline, and remained within the normal range throughout the treatment period. No treatment discontinuation or hospitalization due to hyperkalemia was observed.
CONCLUSIONS: In non-diabetic CKD patients, finerenone showed good effectiveness and safety within a 3-month follow-up period. This study provides valuable real-world evidence supporting the use of finerenone in non-diabetic CKD and highlights the need for future large-scale prospective research to further validate its efficacy.
METHODS: This retrospective, real-world analysis included non-diabetic CKD patients receiving finerenone. The main clinical outcomes assessed were changes in urinary albumin-to-creatinine ratio (UACR) and estimated glomerular filtration rate (eGFR). Serum potassium (sK+) levels were also monitored. Data were collected at baseline, and then at 1 month and 3 months following treatment initiation.
RESULTS: Totally, 16 patients were included. There was a notable decrease in UACR from 1-month post-treatment, with a further reduction at 3 months, resulting in a median reduction of 200.41 mg/g (IQR, 84.04-1057.10 mg/g; P = 0.028; percent change, 44.52% [IQR, 31.79-65.42%]). The average eGFR at baseline was 80.16 ml/min/1.73m2, with no significant change after 1 month (80.72 ml/min/1.73m2, P = 0.594) and a slight numerical increase to 83.45 ml/min/1.73m2 (P = 0.484) after 3 months. During the 3-month follow-up, sK+ levels showed only minor fluctuations, with no significant differences compared to baseline, and remained within the normal range throughout the treatment period. No treatment discontinuation or hospitalization due to hyperkalemia was observed.
CONCLUSIONS: In non-diabetic CKD patients, finerenone showed good effectiveness and safety within a 3-month follow-up period. This study provides valuable real-world evidence supporting the use of finerenone in non-diabetic CKD and highlights the need for future large-scale prospective research to further validate its efficacy.
摘要：
背景：Finerenone，非甾体盐皮质激素受体拮抗剂，先前已证明其在与糖尿病相关的慢性肾脏疾病（CKD）中的疗效和安全性。鉴于其治疗潜力,在非糖尿病CKD患者的临床实践中已经初步探索了finetenone。该人群的有效性和安全性需要在现实世界中进行进一步调查。
方法：本回顾性研究，真实世界分析包括接受finetenone治疗的非糖尿病CKD患者.评估的主要临床结果是尿白蛋白与肌酐比值（UACR）和估计的肾小球滤过率（eGFR）的变化。还监测血清钾(sK+)水平。数据在基线时收集，然后在治疗开始后1个月和3个月。
结果：完全，包括16例患者。治疗后1个月，UACR显着下降，在3个月时进一步减少，导致中位数降低200.41mg/g(IQR，84.04-1057.10mg/g；P=0.028；百分比变化，44.52%[IQR，31.79-65.42%]）。基线时平均eGFR为80.16ml/min/1.73m2，1个月后无明显变化（80.72ml/min/1.73m2，P=0.594），3个月后数值略有增加，为83.45ml/min/1.73m2（P=0.484）。在3个月的随访中，sK+水平仅显示轻微波动，与基线相比没有显着差异，并在整个治疗期间保持在正常范围内。没有观察到由于高钾血症而停止治疗或住院。
结论：在非糖尿病CKD患者中，finerenone在3个月的随访期内显示出良好的有效性和安全性.这项研究提供了有价值的真实世界证据，支持在非糖尿病性CKD中使用finetenone，并强调了未来大规模前瞻性研究以进一步验证其疗效的必要性。
方法：本回顾性研究，真实世界分析包括接受finetenone治疗的非糖尿病CKD患者.评估的主要临床结果是尿白蛋白与肌酐比值（UACR）和估计的肾小球滤过率（eGFR）的变化。还监测血清钾(sK+)水平。数据在基线时收集，然后在治疗开始后1个月和3个月。
结果：完全，包括16例患者。治疗后1个月，UACR显着下降，在3个月时进一步减少，导致中位数降低200.41mg/g(IQR，84.04-1057.10mg/g；P=0.028；百分比变化，44.52%[IQR，31.79-65.42%]）。基线时平均eGFR为80.16ml/min/1.73m2，1个月后无明显变化（80.72ml/min/1.73m2，P=0.594），3个月后数值略有增加，为83.45ml/min/1.73m2（P=0.484）。在3个月的随访中，sK+水平仅显示轻微波动，与基线相比没有显着差异，并在整个治疗期间保持在正常范围内。没有观察到由于高钾血症而停止治疗或住院。
结论：在非糖尿病CKD患者中，finerenone在3个月的随访期内显示出良好的有效性和安全性.这项研究提供了有价值的真实世界证据，支持在非糖尿病性CKD中使用finetenone，并强调了未来大规模前瞻性研究以进一步验证其疗效的必要性。
